XNAS · Healthcare · Biotechnology
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -1.23 | -1.23 | +0.00% | $0 | ➖ Inline | +6.97% | -19.95% | — |
| 2026-03-09 | Q4 2025 | -1.66 | -1.25 | +24.70% | $0 | ✅ Beat | -0.75% | -0.42% | +3.04% |
| 2025-11-12 |
| Q3 2025 |
| -1.74 |
| -1.90 |
| -9.20% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -1.42 | -1.44 | -1.41% | $0 | ❌ Miss | +1.71% | +0.67% | +12.58% |
| 2025-03-11 | Q4 2024 | -1.22 | -0.78 | +36.07% | $0 | ✅ Beat | +0.44% | -7.99% | -17.30% |
| 2024-11-07 | Q3 2024 | -0.95 | -1.15 | -21.05% | $0 | ❌ Miss | +1.40% | -5.24% | -17.71% |
| 2024-08-06 | Q2 2024 | -1.26 | -0.90 | +28.57% | $0 | ✅ Beat | -8.76% | +0.08% | -4.10% |
| 2024-05-07 | Q1 2024 | -1.52 | -0.83 | +45.39% | $0 | ✅ Beat | +6.59% | +8.10% | +17.17% |
Showing last 8 quarters.